For those with inoperable malignant pleural mesothelioma, Alimta (permetrexed) combined with cisplatin remains the top treatment. Japanese researchers recently analyzed the results of 30 patients taking either Gemzar or the Alimta combination and compared complications, disease control and survival rates.
Thirty mesothelioma cases were examined featuring 13 patients taking Gemzar and the remaining 17 taking Alimta and cisplatin. Serious side effects occurred from use of both drugs, but Gemzar users experienced complications more often as well as a shorter survival rate.
The results benefit both current users of Alimta and those recently diagnosed. For some, it serves as an affirmation that they’re pursuing the correct treatment option and for others provides a guide in the decision-making process.
To view the study, click here.
To view the news release, click here.